Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis-Reference-Cited by-同舟云学术

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

Published:2015-03-24 Issue:6 Volume:29 Page:1344-1349
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Palandri F,Latagliata R,Polverelli N,Tieghi A,Crugnola M,Martino B,Perricone M,Breccia M,Ottaviani E,Testoni N,Merli F,Aversa F,Alimena G,Cavo M,Martinelli G,Catani L,Baccarani M,Vianelli N

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201587.pdf

Reference35 articles.

1. Palandri F, Polverelli N, Ottaviani E, Castagnetti F, Baccarani M, Vianelli N . Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica 2010; 95: 1038–1040.

2. Millard FE, Hunter CS, Anderson M, Edelman MJ, Kosty MP, Luiken GA et al. Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 1990; 33: 27–31.

3. Giona F, Teofili L, Capodimonti S, Laurino M, Martini M, Marzella D et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood 2014; 123: 3677–3679.

4. Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, Vianelli N et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol 2014; 89: 306–309.

5. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352–375.

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24

2. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN);Annals of Hematology;2024-07-05

3. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-07

4. Management of thrombosis in myeloproliferative neoplasia;HEMATOLOGIE;2024

5. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study;Leukemia;2024-02-06